Intratumoral injection of L19-IL2 and L19-TNF (both cytokines combining the human monoclonal antibody fragment L19) cytokine combination in patients with stage IIIC and IVM1a metastatic melanoma who were not candidates for surgery has shown that, in 20 efficacy-evaluable patients, 32 melanoma lesions achieved complete responses upon intralesional administration and complete responses in 7/13 (53.8%) noninjected lesions [29]. This evidence concerns the gene IL2 and melanoma.